Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2009-11-30
2020-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Ribavirin Pregnancy Registry
NCT00114712
A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Infants
NCT00001135
Tenofovir Gel in Pregnancy and Lactation
NCT01136759
A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies
NCT00000869
Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
NCT00246610
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VIBATIV treated pregnant women
Women treated with telavancin (any dose or duration) during pregnancy.
VIBATIV
Observational
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VIBATIV
Observational
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Outcome of pregnancy is unknown at the time of enrollment
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cumberland Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam Haberle, PhD
Role: PRINCIPAL_INVESTIGATOR
Cumberland Pharmaceuticals, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cumberland Pharmaceuticals Inc.
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0113
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.